Sutro Biopharma (STRO) was upgraded by Truist Financial Corporation to "strong-buy".
Sutro Biopharma (STRO) had its price target raised by Deutsche Bank Aktiengesellschaft from $51.00 to $55.00. They now have a "buy" rating on the stock.
Sutro Biopharma (STRO) was upgraded by Wells Fargo & Company from "equal weight" to "overweight". They now have a $27.00 price target on the stock, up from $8.00.
Sutro Biopharma (STRO) was upgraded by HC Wainwright from "neutral" to "buy". They now have a $28.00 price target on the stock, up from $10.00.
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]